DE602004027888D1 - Anti-cd70 antikörper-arzneimittelkonjugate und ihr - Google Patents
Anti-cd70 antikörper-arzneimittelkonjugate und ihrInfo
- Publication number
- DE602004027888D1 DE602004027888D1 DE602004027888T DE602004027888T DE602004027888D1 DE 602004027888 D1 DE602004027888 D1 DE 602004027888D1 DE 602004027888 T DE602004027888 T DE 602004027888T DE 602004027888 T DE602004027888 T DE 602004027888T DE 602004027888 D1 DE602004027888 D1 DE 602004027888D1
- Authority
- DE
- Germany
- Prior art keywords
- disclosed
- antibody
- antibody medicament
- pharmaceutical compositions
- conjugates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102100025221 CD70 antigen Human genes 0.000 abstract 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44905503P | 2003-02-20 | 2003-02-20 | |
PCT/US2004/005247 WO2004073656A2 (en) | 2003-02-20 | 2004-02-20 | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004027888D1 true DE602004027888D1 (de) | 2010-08-12 |
Family
ID=32908685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004027888T Expired - Lifetime DE602004027888D1 (de) | 2003-02-20 | 2004-02-20 | Anti-cd70 antikörper-arzneimittelkonjugate und ihr |
Country Status (11)
Country | Link |
---|---|
US (6) | US7662387B2 (de) |
EP (3) | EP2100619B1 (de) |
JP (3) | JP5356648B2 (de) |
AT (1) | ATE472338T1 (de) |
AU (1) | AU2004213053C1 (de) |
CA (1) | CA2516455C (de) |
DE (1) | DE602004027888D1 (de) |
DK (1) | DK1594542T3 (de) |
ES (2) | ES2347959T3 (de) |
HK (1) | HK1155070A1 (de) |
WO (1) | WO2004073656A2 (de) |
Families Citing this family (177)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58103228A (ja) * | 1981-12-16 | 1983-06-20 | Kaga Tsushin Kogyo Kk | 光スイツチ方法 |
US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
CN101671335A (zh) | 2001-05-31 | 2010-03-17 | 梅达莱克斯公司 | 细胞毒素、其有用的前体药物、连接基团和稳定剂 |
US7226594B2 (en) * | 2001-11-07 | 2007-06-05 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
ES2347959T3 (es) * | 2003-02-20 | 2010-11-26 | Seattle Genetics, Inc. | Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer. |
US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
JP2007525434A (ja) | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | T細胞、免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体およびその使用。 |
US20050282168A1 (en) * | 2003-09-29 | 2005-12-22 | Wyeth | Cell surface molecules as markers and therapeutic agents against kidney cancers |
SG149815A1 (en) | 2003-11-06 | 2009-02-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005077462A2 (en) * | 2004-02-09 | 2005-08-25 | The Cbr Institute For Biomedical Research, Inc. | Cd70 inhibition for the treatment and prevention of inflammatory bowel disease |
BRPI0510909A2 (pt) * | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
EP1799262A4 (de) * | 2004-10-15 | 2009-10-21 | Seattle Genetics Inc | Anti-cd70-antikörper und seine verwendung zur behandlung und vorbeugung von krebserkrankungen und immunstörungen |
US7641903B2 (en) * | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US7462697B2 (en) * | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
WO2006132670A2 (en) * | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
DE602005022928D1 (de) * | 2004-11-30 | 2010-09-23 | Abgenix Inc | Antikörper gegen gpnmb und ihre verwendungen |
GB0501741D0 (en) * | 2005-01-27 | 2005-03-02 | Binding Site The Ltd | Antibody |
PL1863905T3 (pl) | 2005-03-17 | 2016-07-29 | Ucl Business Plc | Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro |
US8350009B2 (en) | 2005-03-31 | 2013-01-08 | Agensys, Inc. | Antibodies and related molecules that bind to 161P2F10B proteins |
EP2444099A1 (de) * | 2005-03-31 | 2012-04-25 | Agensys, Inc. | An 161P2F10B-Proteine bindende Antikörper und zugehörige Moleküle |
AU2012211500B2 (en) * | 2005-04-19 | 2014-10-23 | Seagen Inc. | Humanized anti-CD70 binding agents and uses thereof |
DK1871418T3 (da) | 2005-04-19 | 2014-06-10 | Seattle Genetics Inc | Humaniserede anti-cd70-bindende midler og anvendelser deraf |
JP5027804B2 (ja) | 2005-05-26 | 2012-09-19 | シアトル ジェネティクス,インコーポレーテッド | ヒト化抗cd40抗体およびその使用方法 |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
CA2614436C (en) | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
PL3248613T3 (pl) | 2005-07-18 | 2022-04-19 | Seagen Inc. | Koniugaty β-glukuronid-linker-lek |
CA2623236A1 (en) * | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
AU2006294554B2 (en) * | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
AU2006315580A1 (en) * | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen |
WO2007062138A2 (en) * | 2005-11-23 | 2007-05-31 | Applera Corporation | Methods and compositions for treating diseases targeting human prominin-1(cd133) |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
MX2009002856A (es) * | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Conjugados polimericos que contienen porciones cargadas positivamente. |
JP2010510810A (ja) * | 2006-11-27 | 2010-04-08 | エンゾン ファーマスーティカルズ インコーポレイテッド | ポリマー低分子干渉rna複合体 |
PT2099823E (pt) | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Agentes de ligação ao alvo variantes e suas utilizações |
NZ578354A (en) * | 2006-12-14 | 2012-01-12 | Medarex Inc | Antibody-partner molecule conjugates that bind cd70 and uses thereof |
SG183023A1 (en) | 2007-07-16 | 2012-08-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
EP2641618A3 (de) | 2007-07-16 | 2013-10-23 | Genentech, Inc. | Humanisierte Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren |
US9901567B2 (en) * | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
US20090035848A1 (en) * | 2007-08-03 | 2009-02-05 | Robert Hickey | Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products |
WO2009026274A1 (en) * | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
EP3241846B1 (de) * | 2007-10-04 | 2022-02-23 | ZymoGenetics, Inc. | B7-familienmitglied zb7h6 sowie zugehörige zusammensetzungen und verfahren |
CA2702555A1 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
EP2078492A1 (de) * | 2008-01-11 | 2009-07-15 | Roche Diagnostics GmbH | Bandkassette für ein medizinisches Handgerät und Blutzuckermesssystem |
IL295449A (en) | 2008-01-31 | 2022-10-01 | Genentech Inc | and fusion antibody-drug-cd79b engineered antibodies cysteine- |
NO2842575T3 (de) | 2008-03-18 | 2018-02-24 | ||
AU2009234267B2 (en) | 2008-04-11 | 2014-10-30 | Seagen Inc. | Detection and treatment of pancreatic, ovarian and other cancers |
CA2723197C (en) | 2008-05-02 | 2017-09-19 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
ES2438495T3 (es) | 2008-09-08 | 2014-01-17 | Psma Development Company, L.L.C. | Compuestos para exterminar células cancerosas que expresan PSMA, resistentes a taxano |
BRPI0921687A8 (pt) | 2008-11-03 | 2022-11-08 | Syntarga Bv | Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero. |
WO2010096394A2 (en) * | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
IN2012DN03025A (de) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
WO2011038159A2 (en) * | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
JP6046494B2 (ja) * | 2010-02-08 | 2016-12-14 | アジェンシス,インコーポレイテッド | 161p2f10bタンパク質に結合する抗体薬物コンジュゲート(adc) |
CA3188287A1 (en) | 2010-03-26 | 2011-09-29 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
US9133239B2 (en) | 2010-04-20 | 2015-09-15 | The Research Foundation For The State University Of New York | Compositions and methods for inhibiting matrix metalloproteinase (MMP)-mediated cell migration |
ES2815678T3 (es) | 2010-04-21 | 2021-03-30 | Syntarga Bv | Conjugados de análogos de CC-1065 y conectores bifuncionales |
AU2015271991B2 (en) * | 2010-09-29 | 2017-08-17 | Philogen S.P.A. | Thiazolidine linker for the conjugation of drugs to antibodies |
CA2811667C (en) * | 2010-09-29 | 2017-09-05 | Philogen S.P.A. | Thiazolidine linker for the conjugation of drugs to antibodies |
EP2632482A4 (de) * | 2010-10-27 | 2015-05-27 | Baylor College Medicine | Chimäre cd27-rezeptoren zur neuausrichtung von t-zellen an cd70-positiven malignomen |
US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
EP2663647A4 (de) | 2011-01-14 | 2015-08-19 | Redwood Bioscience Inc | Aldehydmarkierte immunoglobulinpolypeptide und verwendungsverfahren dafür |
WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
WO2012106368A2 (en) | 2011-01-31 | 2012-08-09 | The Regents Of The University Of California | Methods for inhibiting prostate cancer |
BR112013021562B1 (pt) | 2011-03-16 | 2023-01-10 | Argenx Bvba | Anticorpos para cd70 |
EP2714684B1 (de) * | 2011-05-27 | 2018-09-05 | Ambrx, Inc. | Zusammensetzungen, enthaltend mit nichtnatürlichen aminosäuren verknüpfte dolastatin-derivate, sowie verfahren dafür und anwendungen davon |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
JP5926374B2 (ja) | 2011-06-10 | 2016-05-25 | メルサナ セラピューティクス,インコーポレイティド | タンパク質−高分子−薬剤コンジュゲート |
JP6251678B2 (ja) | 2011-09-22 | 2017-12-20 | アムジエン・インコーポレーテツド | Cd27l抗原結合タンパク質 |
WO2013067055A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
CA2863216C (en) * | 2012-01-09 | 2020-06-02 | Covx Technologies Ireland Limited | Mutant antibodies and conjugation thereof |
SG11201408494UA (en) * | 2012-06-19 | 2015-02-27 | Ambrx Inc | Anti-cd70 antibody drug conjugates |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
EP4063391A1 (de) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit-antikörper und verwendungen davon |
CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
CA2892748A1 (en) | 2012-11-29 | 2014-06-05 | Bayer Healthcare Llc | Humanized monoclonal antibodies against activated protein c and uses thereof |
US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
KR102218494B1 (ko) * | 2013-03-15 | 2021-02-19 | 인트린식 라이프사이언시스, 엘엘씨 | 항-헵시딘 항체 및 그의 용도 |
GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
US20140363454A1 (en) * | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-Drug Conjugates, Compositions and Methods of Use |
BR112015032200A2 (pt) * | 2013-06-24 | 2017-11-21 | Hanwha Chemical Corp | conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo |
EP3041868A2 (de) | 2013-09-05 | 2016-07-13 | Aduro Biotech Holdings, Europe B.V. | Cd70-bindende peptide sowie verfahren, prozess und verwendung im zusammenhang damit |
CN105813655B (zh) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | 蛋白-聚合物-药物缀合物 |
EP3082870B1 (de) * | 2013-12-20 | 2019-10-23 | The University of Bristol | Konjugate zur behandlung entzündlicher erkrankungen und identifizierung von patienten, die wahrscheinlich von einer derartigen behandlung profitieren |
CN105899235B (zh) | 2014-01-10 | 2019-08-30 | 斯索恩生物制药有限公司 | 用于纯化cys连接的抗体-药物缀合物的方法 |
LT3069735T (lt) | 2014-01-10 | 2018-06-11 | Synthon Biopharmaceuticals B.V. | Duokarmicino antikūno-vaisto konjugatai, skirti šlapimo pūslės vėžio gydymui |
CN105899537A (zh) | 2014-01-10 | 2016-08-24 | 博笛生物科技(北京)有限公司 | 靶向表达egfr的肿瘤的化合物和组合物 |
DK2948183T3 (en) | 2014-01-10 | 2016-06-27 | Synthon Biopharmaceuticals Bv | DUOCARMYCIN ADCS USED IN TREATMENT OF ENDOMETRY CANCER |
EP3122757B1 (de) | 2014-02-28 | 2023-09-06 | Hangzhou Dac Biotech Co., Ltd | Geladene linker und deren verwendungen zur konjugation |
US9260478B2 (en) | 2014-04-04 | 2016-02-16 | Shanghui Hu | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis |
MX2016013158A (es) | 2014-04-10 | 2017-04-27 | Seattle Children's Hospital (Dba Seattle Children's Res Institute) | Productos de celulas t modificadas de genes de composicion definida. |
CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
SG11201700365TA (en) * | 2014-07-24 | 2017-02-27 | Genentech Inc | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
EP3191131A4 (de) | 2014-08-21 | 2018-09-05 | The General Hospital Corporation | Tumornekrosefaktor-superfamilie und tnf-like-ligand-muteine sowie verfahren zur herstellung und verwendung davon |
US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
US10323088B2 (en) | 2014-09-22 | 2019-06-18 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
ES2796903T3 (es) | 2014-09-23 | 2020-11-30 | Hoffmann La Roche | Procedimiento de uso de inmunoconjugados anti-CD79b |
EP3212668B1 (de) | 2014-10-31 | 2020-10-14 | AbbVie Biotherapeutics Inc. | Anti-cs1-antikörper und antikörperwirkstoffkonjugate |
CA2970155A1 (en) | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
CN107249643A (zh) | 2014-12-09 | 2017-10-13 | 艾伯维公司 | 具有细胞渗透性的bcl‑xl抑制剂的抗体药物缀合物 |
WO2016149485A1 (en) | 2015-03-17 | 2016-09-22 | The Regents Of The University Of California | Novel chemoimmunotherapy for epithelial cancer |
CN107667120B (zh) | 2015-03-17 | 2022-03-08 | 纪念斯隆-凯特林癌症中心 | 抗muc16抗体及其应用 |
EP3310787B9 (de) * | 2015-06-18 | 2020-07-01 | Ramot at Tel-Aviv University Ltd. | Markierungsgiebelheteroaromatische arzneimittel und konjugate davon |
CN113350518A (zh) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
CN108174604B (zh) | 2015-08-07 | 2023-06-23 | 西雅图儿童医院(Dba西雅图儿童研究所) | 用于实体瘤靶向的双特异性car t细胞 |
WO2017087391A1 (en) | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
JP2019500327A (ja) | 2015-11-30 | 2019-01-10 | アッヴィ・インコーポレイテッド | 抗huLRRC15抗体薬物コンジュゲート及びその使用方法 |
EP3383910A1 (de) | 2015-11-30 | 2018-10-10 | AbbVie Inc. | Anti-hulrrc15-antikörper-wirkstoff-konjugate und verfahren zu deren verwendung |
WO2017147247A1 (en) * | 2016-02-23 | 2017-08-31 | Pires Eusebio S | Anti-sas1b antibodies and methods of use |
CN108697799A (zh) | 2016-03-22 | 2018-10-23 | 生态学有限公司 | 抗lgr5单克隆抗体的施用 |
JP2019515677A (ja) | 2016-04-26 | 2019-06-13 | アール.ピー.シェーラー テクノロジーズ エルエルシー | 抗体複合体ならびにそれを作製および使用する方法 |
DK3458102T3 (da) | 2016-05-17 | 2020-07-27 | Abbvie Biotherapeutics Inc | Anti-cmet-antistoflægemiddelkonjugater og fremgangsmåder til anvendelse deraf |
US20200147235A1 (en) | 2016-06-08 | 2020-05-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
JP2019526529A (ja) | 2016-06-08 | 2019-09-19 | アッヴィ・インコーポレイテッド | 抗b7−h3抗体及び抗体薬物コンジュゲート |
CR20180614A (es) | 2016-06-08 | 2019-07-29 | Abbvie Inc | Conjugados de anticuerpo y fármaco anti-egfr |
CN109600993A (zh) | 2016-06-08 | 2019-04-09 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
WO2017214301A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
US20200121803A1 (en) | 2016-06-08 | 2020-04-23 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
PE20190177A1 (es) | 2016-06-08 | 2019-02-01 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco |
CN109641962A (zh) | 2016-06-08 | 2019-04-16 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
CN109562169A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
CN110022886A (zh) * | 2016-10-05 | 2019-07-16 | 王天欣 | 一种治疗自身免疫性疾病和过敏的方法和试剂 |
JP7138350B2 (ja) | 2016-11-14 | 2022-09-16 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | 共役連結体、該連結体を含有する細胞結合分子-薬物共役体、並びに該共役体及び連結体の使用及び製造方法 |
KR102015524B1 (ko) * | 2016-12-26 | 2019-08-29 | 인터올리고 주식회사 | 압타머-약물 콘쥬게이트 및 그 용도 |
NZ756323A (en) | 2017-02-28 | 2022-07-01 | Seagen Inc | Cysteine mutated antibodies for conjugation |
WO2018178277A1 (en) | 2017-03-29 | 2018-10-04 | Avicenna Oncology Gmbh | New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
EP3621981A2 (de) | 2017-05-12 | 2020-03-18 | CRISPR Therapeutics AG | Materialien und verfahren zur manipulation von zellen und deren verwendungen in der immunonkologie |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
WO2018218076A1 (en) * | 2017-05-26 | 2018-11-29 | Janux Therapeutics, Inc. | Modified antibodies |
GB2567613A (en) | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
US20230158070A1 (en) | 2018-01-30 | 2023-05-25 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
EP3762400A4 (de) * | 2018-03-08 | 2022-03-16 | Magenta Therapeutics, Inc. | Anti-cd252-antikörper, konjugate und verfahren zur verwendung |
AU2019240403A1 (en) | 2018-03-23 | 2020-10-08 | Seagen Inc. | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
PE20210320A1 (es) | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
JP2020019723A (ja) * | 2018-07-30 | 2020-02-06 | 国立大学法人 鹿児島大学 | 抗CD70抗体とIgG結合ペプチドの複合体 |
CN112638944A (zh) | 2018-08-23 | 2021-04-09 | 西进公司 | 抗tigit抗体 |
CA3111397A1 (en) | 2018-09-06 | 2020-03-12 | Daiichi Sankyo Company, Limited | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
FR3085952B1 (fr) | 2018-09-17 | 2020-10-30 | Centre Nat Rech Scient | Conjugue anticorps-medicament comprenant des derives de quinoline |
EP3870235A1 (de) * | 2018-10-24 | 2021-09-01 | F. Hoffmann-La Roche AG | Konjugierte chemische abbauauslöser und verwendungsverfahren |
TW202038958A (zh) | 2018-12-18 | 2020-11-01 | 比利時商阿根思公司 | Cd70組合治療 |
CA3138633A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
US20230071196A1 (en) | 2019-05-21 | 2023-03-09 | Novartis Ag | Variant cd58 domains and uses thereof |
WO2020236792A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Cd19 binding molecules and uses thereof |
US20200384278A1 (en) * | 2019-06-04 | 2020-12-10 | Jerome Canady Research Institute for Advanced Biological and Technological Sciences | Method for Combination Cold Atmospheric Plasma and CAR-T Therapy |
JP2022543669A (ja) | 2019-08-08 | 2022-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規抗原結合分子フォーマット |
EP4041312A4 (de) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Verfahren zur behandlung einer augenstörung |
TW202134277A (zh) | 2019-11-05 | 2021-09-16 | 美商再生元醫藥公司 | N—端scFv多特異性結合分子 |
TW202138388A (zh) | 2019-12-30 | 2021-10-16 | 美商西根公司 | 以非海藻糖苷化抗-cd70抗體治療癌症之方法 |
US20230330248A1 (en) * | 2020-03-06 | 2023-10-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
CA3174103A1 (en) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
WO2021195513A1 (en) | 2020-03-27 | 2021-09-30 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune disorders |
WO2021245603A1 (en) * | 2020-06-04 | 2021-12-09 | Crispr Therapeutics Ag | Anti-cd70 antibodies and uses thereof |
WO2022043538A1 (en) | 2020-08-29 | 2022-03-03 | argenx BV | Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor |
CN116261590A (zh) | 2020-09-29 | 2023-06-13 | 信达生物制药(苏州)有限公司 | 抗cd3抗体以及其用途 |
AU2021376218A1 (en) | 2020-11-08 | 2023-06-15 | Seagen Inc. | Combination Therapy |
US20230051406A1 (en) | 2020-11-13 | 2023-02-16 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
AU2021388155A1 (en) | 2020-11-25 | 2023-06-15 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
EP4301782A1 (de) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44-antikörper und deren verwendungen |
JPWO2022191313A1 (de) | 2021-03-12 | 2022-09-15 | ||
EP4319820A1 (de) | 2021-04-10 | 2024-02-14 | Profoundbio Us Co. | Folr1-bindende wirkstoffe, konjugate davon und verfahren zur verwendung davon |
CA3216459A1 (en) * | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
AU2022324456A1 (en) | 2021-08-05 | 2024-02-15 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
WO2023034571A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
AU2022339667A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
EP0216846B2 (de) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
DE68926888T2 (de) | 1988-01-22 | 1997-01-09 | Zymogenetics Inc | Verfahren zur Herstellung von sekretierten Rezeptoranalogen |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
EP0428534B1 (de) | 1988-06-14 | 1995-03-29 | Cetus Oncology Corporation | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
IL91501A (en) | 1988-09-02 | 1998-03-10 | Dyax Corp | Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
EP0739904A1 (de) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispezifische Reagenzien für die AIDS-Therapie |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JP3583420B2 (ja) | 1990-10-05 | 2004-11-04 | メダレツクス・インコーポレーテツド | 二特異的試薬を用いた標的免疫化 |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
EP0517895B1 (de) | 1990-12-14 | 1996-11-20 | Cell Genesys, Inc. | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
ES2093778T3 (es) | 1991-04-26 | 1997-01-01 | Surface Active Ltd | Nuevos anticuerpos y metodos para su uso. |
EP0519596B1 (de) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
DK0627940T3 (da) | 1992-03-05 | 2003-09-01 | Univ Texas | Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2102401A1 (en) | 1992-06-09 | 1993-12-10 | Friedrich Hoppe | Latch and lockset system |
US5573924A (en) * | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
ATE300610T1 (de) | 1994-01-31 | 2005-08-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
AU3382595A (en) | 1994-07-29 | 1996-03-04 | Smithkline Beecham Corporation | Novel compounds |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US6111166A (en) | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
EP0822830B1 (de) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ES2195036T3 (es) | 1995-12-22 | 2003-12-01 | Bristol Myers Squibb Co | Conectores de hidrazona ramificados. |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
DE69832158T2 (de) | 1997-02-25 | 2006-08-10 | Arizona Board Of Regents, Tempe | Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18 |
JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6342221B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody conjugate compositions for selectively inhibiting VEGF |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
CN1321768A (zh) | 2000-04-29 | 2001-11-14 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶21和编码这种多肽的多核苷酸 |
EP1358349A2 (de) | 2000-06-05 | 2003-11-05 | Avalon Pharmaceuticals | Bestimmung von krebsgenen und therapeutisches screeningverfahren das signaturen von gensätzen verwendet |
WO2002036142A2 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
JP2004536786A (ja) * | 2001-03-02 | 2004-12-09 | メディミューン,インコーポレイテッド | インテグリンαvβ3拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法 |
US20030083263A1 (en) * | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
US7261892B2 (en) * | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
JP4446036B2 (ja) * | 2001-11-27 | 2010-04-07 | ウーセーベー ファルマ ソシエテ アノニム | 上皮誘導性癌の治療のための薬剤組成物 |
ES2544527T3 (es) * | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
ES2347959T3 (es) | 2003-02-20 | 2010-11-26 | Seattle Genetics, Inc. | Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer. |
US20080025989A1 (en) * | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
AU2003237076A1 (en) | 2003-05-23 | 2004-12-13 | Stichting Sanquin Bloedvoorziening | Therapeutical use of anti-cd70 antibody for treating or preventing aids |
SG149815A1 (en) | 2003-11-06 | 2009-02-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005077462A2 (en) | 2004-02-09 | 2005-08-25 | The Cbr Institute For Biomedical Research, Inc. | Cd70 inhibition for the treatment and prevention of inflammatory bowel disease |
CN101010179A (zh) | 2004-08-05 | 2007-08-01 | 富士胶片株式会社 | 用于制造涂料的设备 |
EP1799262A4 (de) | 2004-10-15 | 2009-10-21 | Seattle Genetics Inc | Anti-cd70-antikörper und seine verwendung zur behandlung und vorbeugung von krebserkrankungen und immunstörungen |
US7641903B2 (en) * | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US8337838B2 (en) * | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
EP1856239A1 (de) * | 2005-02-23 | 2007-11-21 | Alfred Michael Vegvary | Überwachungssystem zur wahrnehmung von mikroorganismen |
DK1871418T3 (da) * | 2005-04-19 | 2014-06-10 | Seattle Genetics Inc | Humaniserede anti-cd70-bindende midler og anvendelser deraf |
CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
NZ578354A (en) | 2006-12-14 | 2012-01-12 | Medarex Inc | Antibody-partner molecule conjugates that bind cd70 and uses thereof |
CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
US10455570B2 (en) | 2016-09-26 | 2019-10-22 | Ofinno, Llc | Selection of DCI based upon TTI |
US11910104B2 (en) | 2019-04-19 | 2024-02-20 | ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA, A BODY CORPORATE | All-in-focus imager and associated method |
-
2004
- 2004-02-20 ES ES04713441T patent/ES2347959T3/es not_active Expired - Lifetime
- 2004-02-20 DE DE602004027888T patent/DE602004027888D1/de not_active Expired - Lifetime
- 2004-02-20 EP EP09004484.3A patent/EP2100619B1/de not_active Expired - Lifetime
- 2004-02-20 CA CA2516455A patent/CA2516455C/en not_active Expired - Lifetime
- 2004-02-20 WO PCT/US2004/005247 patent/WO2004073656A2/en active Application Filing
- 2004-02-20 EP EP10009951.4A patent/EP2289559B1/de not_active Expired - Lifetime
- 2004-02-20 AT AT04713441T patent/ATE472338T1/de active
- 2004-02-20 ES ES10009951.4T patent/ES2457538T3/es not_active Expired - Lifetime
- 2004-02-20 JP JP2006503790A patent/JP5356648B2/ja not_active Expired - Lifetime
- 2004-02-20 US US10/546,304 patent/US7662387B2/en not_active Expired - Lifetime
- 2004-02-20 DK DK04713441.6T patent/DK1594542T3/da active
- 2004-02-20 AU AU2004213053A patent/AU2004213053C1/en not_active Expired
- 2004-02-20 EP EP04713441A patent/EP1594542B1/de not_active Expired - Lifetime
-
2009
- 2009-05-15 US US12/467,182 patent/US20100183636A1/en not_active Abandoned
- 2009-12-10 US US12/635,571 patent/US20100150925A1/en not_active Abandoned
- 2009-12-10 US US12/635,607 patent/US9345785B2/en active Active
-
2010
- 2010-03-11 HK HK11109282.5A patent/HK1155070A1/xx not_active IP Right Cessation
- 2010-10-07 JP JP2010227978A patent/JP2011012080A/ja active Pending
-
2012
- 2012-05-31 US US13/485,536 patent/US8535678B2/en not_active Expired - Lifetime
- 2012-06-07 US US13/491,475 patent/US8609104B2/en not_active Expired - Lifetime
-
2013
- 2013-06-19 JP JP2013128242A patent/JP2013189472A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004027888D1 (de) | Anti-cd70 antikörper-arzneimittelkonjugate und ihr | |
WO2006044643A3 (en) | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders | |
LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
CY1119865T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον | |
WO2006113909A3 (en) | Humanized anti-cd70 binding agents and uses thereof | |
WO2005117986A3 (en) | Antibody drug conjugates and methods | |
WO2004018000A3 (en) | Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents | |
WO2007100385A3 (en) | Macrocyclic depsipeptide antibody-drug conjugates and methods | |
EP2354163A3 (de) | Konjugate von Duocarmycin und Anti-CD70 oder Anti-PSMA Antikörpern | |
EA200601761A1 (ru) | Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения | |
WO2005002516A3 (en) | Leukocyte internalized peptide-drug conjugates | |
CL2022003715A1 (es) | Tubulisinas y conjugados de proteinas-tubulisina |